Health Economics Journal

Overview
Identity
View All

publication venue for

Using relative distributions to investigate the body mass index in England and Canada 2007
Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada 2005
Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator 1997
Why do drinkers earn more? Job characteristics as a possible link. 33:1133-1152. 2024
ADHD misdiagnosis: Causes and mitigators. 31:1926-1953. 2022
Consolidation of primary care physicians and its impact on healthcare utilization. 30:1361-1373. 2021
Payment models in primary health care: A driver of the quantity and quality of medical laboratory utilization. 28:1166-1178. 2019
Here comes the SUN: Self‐assessed unmet need, worsening health outcomes, and health care inequity. 28:727-735. 2019
Transforming Latent Utilities to Health Utilities: East Does Not Meet West (vol 26, pg 1524, 2017). 27:E181-E181. 2018
Transforming Latent Utilities to Health Utilities: East Does Not Meet West. 26:1524-1533. 2017
Will the Need‐Based Planning of Health Human Resources Currently Undertaken in Several Countries Lead to Excess Supply and Inefficiency? A Comment on Basu and Pak. 26:818-821. 2017
Physician Payment Contracts in the Presence of Moral Hazard and Adverse Selection: The Theory and Its Application in Ontario. 25:1326-1340. 2016
Empirical Testing of the External Validity of a Discrete Choice Experiment to Determine Preferred Treatment Option: The Case of Sleep Apnea. 24:951-965. 2015
THE IMPACT OF TECHNOLOGICAL INTENSITY OF SERVICE PROVISION ON PHYSICIAN EXPENDITURES: AN EXPLORATORY INVESTIGATION. 23:1224-1241. 2014
PHYSICIAN RESPONSE TO PAY-FOR-PERFORMANCE: EVIDENCE FROM A NATURAL EXPERIMENT. 23:962-978. 2014
LINK BETWEEN PAY FOR PERFORMANCE INCENTIVES AND PHYSICIAN PAYMENT MECHANISMS: EVIDENCE FROM THE DIABETES MANAGEMENT INCENTIVE IN ONTARIO. 22:1417-1439. 2013
UNCERTAINTY AND THE DECISION MAKER: ASSESSING AND MANAGING THE RISK OF UNDESIRABLE OUTCOMES. 22:1287-1294. 2013
A RESPONSE TO CRÉMIEUX, MEILLEUR, OUELLETTE AND PETIT. 21:1499-1501. 2012
A SECOND LOOK AT PHARMACEUTICAL SPENDING AS DETERMINANTS OF HEALTH OUTCOMES IN CANADA. 21:1477-1495. 2012
ACCOUNTING FOR BETWEEN‐STUDY VARIATION IN INCREMENTAL NET BENEFIT IN VALUE OF INFORMATION METHODOLOGY. 21:1183-1195. 2012
Public and private health‐care financing with alternate public rationing rules. 21:83-100. 2012
Public and private health‐care financing with alternate public rationing rules. 21:83-100. 2012
I dreamed a dream: England reduces health inequalities and wins the world cup. 19:881-885. 2010
Optimal clinical trial design using value of information methods with imperfect implementation. 19:549-561. 2010
How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated‐choice survey. 18:1420-1439. 2009
Inequity in publicly funded physician care: what is the role of private prescription drug insurance?. 18:1218-1232. 2009
Physician labour supply in Canada: a cohort analysis. 18:437-456. 2009
Globally optimal trial design for local decision making. 18:203-216. 2009
Distributional consequences of the transition from age‐based to income‐based prescription drug coverage in British Columbia, Canada. 17:1379-1392. 2008
Publicly funded medical savings accounts: expenditure and distributional impacts in Ontario, Canada. 17:1129-1151. 2008
Cost‐effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate. 17:777-791. 2008
Does free complementary health insurance help the poor to access health care? Evidence from France. 17:203-219. 2008
An opportunity cost approach to sample size calculation in cost‐effectiveness analysis. 17:99-107. 2008
Different dental care setting: does income matter?. 17:109-118. 2008
Expected value of information and decision making in HTA. 16:195-209. 2007
Family income, parenting styles and child behavioural–emotional outcomes. 16:145-162. 2007
Health expenditure growth: reassessing the threat of ageing. 15:947-963. 2006
A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British Columbia. 15:735-742. 2006
Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. 14:327-338. 2005
Access to physician services: does supplemental insurance matter? Evidence from France. 13:669-687. 2004
Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data. 13:461-475. 2004
Using simulation‐based inference with panel data in health economics. 13:101-122. 2004
A view from the bridge: agreement between the SF‐6D utility algorithm and the Health Utilities Index. 12:975-981. 2003
Conservative versus aggressive follow up of mildly abnormal Pap smears: Testing for process utility. 12:879-884. 2003
Double discounting of QALYs. 12:165-169. 2003
Recognising diversity in public preferences: the use of preference sub‐groups in cost‐effectiveness analysis. Authors' reply. 11:653-654. 2002
Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysis. 11:415-430. 2002
On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. 11:185-191. 2002
Is there a kink in consumers' threshold value for cost‐effectiveness in health care?. 11:175-180. 2002
Commentary on Jack Dowie, “Decision validity should determine whether a generic or condition‐specific HRQOL measure is used in health care decisions”. 11:9-12. 2002
Commentary on Jack Dowie, “Decision validity should determine whether a generic or condition‐specific HRQOL measure is used in health care decisions”. 11:13-16. 2002
Opportunity costs and uncertainty in the economic evaluation of health care interventions. 11:23-31. 2002
The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes. 11:55-70. 2002
Cost prediction models for the comparison of two groups. 10:363-366. 2001
Recognizing diversity in public preferences: The use of preference sub‐groups in cost‐effectiveness analysis. 10:317-324. 2001
The role of permanent income and family structure in the determination of child health in Canada. 10:287-302. 2001
Measuring productivity loss days in asthma patients. 9:37-46. 2000
Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem (vol 5, pg 297, 1996). 8:559-559. 1999
The 39 steps: the mystery of health inequalities in the UK. 8:301-308. 1999
‘Our healthier nation’?. 8:289-296. 1999
Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trials data. 8:203-211. 1999
Health care contingent valuation studies: a review and classification of the literature. 7:313-326. 1998
As a matter of fact: evidence-based decision-making unplugged. 6:547-559. 1997
Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group. 6:505-510. 1997
Health economics for the uninitiated - Lockett,T. 6:322-323. 1997
Aboriginal Physician Use in Canada: Location, Orientation and Identity. 6:197-207. 1997
Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem. 5:297-305. 1996
Relative fees and the utilization of physicians' services in Canada. 4:419-438. 1995
A comparison of alternative models of prescription drug utilization. 4:183-198. 1995
Evaluating the NHS Reforms. Edited by Ray Robinson and Julian Le Grand. Policy Journals, Newbury Berks, 1994. No. of pages: 288. ISBN 0‐946967‐43‐1. 3:406-408. 1994
Equitable access to health care: Methodological extensions to the analysis of physician utilization in Canada. 2:87-101. 1993

has subject area

1117 Public Health and Health Services (FoR)
1402 Applied Economics (FoR)
1403 Econometrics (FoR)
Health Policy & Services (Science Metrix)